-+ 0.00%
-+ 0.00%
-+ 0.00%
Kangchen Pharmaceutical announced on November 19 that the company received a clinical trial notice for KC1101 tablets, a Class 1 innovative chemical drug approved by the State Drug Administration, and agreed to conduct clinical trials of this single drug in advanced recurrent or metastatic solid tumors. KC1101 is a TACC3 selective small molecule inhibitor independently developed by the company. Preclinical studies have shown that it has inhibitory effects on tumor growth in various tumor models and has good pharmacogenicity characteristics. The company suggests that there are many uncertainties about the long cycle of drugs from clinical trials to production and marketing, and this development progress will not have a significant impact on recent performance.
Share
Listen to the news
Kangchen Pharmaceutical announced on November 19 that the company received a clinical trial notice for KC1101 tablets, a Class 1 innovative chemical drug approved by the State Drug Administration, and agreed to conduct clinical trials of this single drug in advanced recurrent or metastatic solid tumors. KC1101 is a TACC3 selective small molecule inhibitor independently developed by the company. Preclinical studies have shown that it has inhibitory effects on tumor growth in various tumor models and has good pharmacogenicity characteristics. The company suggests that there are many uncertainties about the long cycle of drugs from clinical trials to production and marketing, and this development progress will not have a significant impact on recent performance.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending